The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.
A study evaluated characteristics of pseudoprogression among patients with cervical cancer treated with ICIs.
Does abemaciclib and letrozole effective slow or stop endometrial cancer cell growth?
All patients will receive mirvetuximab soravtansine and pembrolizumab in this study.
A phase 3 study seeks to evaluate the value of selecting therapy based on molecular profiling.
Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
Screening, preferably with primary HPV testing, should start at age 25 and continue through age 65.
Study results differ from prior research into microRNAs as predictive biomarkers.
This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
A proof-of-principle study confirms presence of TP53 variants ahead of diagnosis.
Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.